Skip to content

辛迪制药

US · SNDX #2947 按市值排名 上市于 2016
12.90 -0.75 -5.49%
实时 - 追踪5344个代码 - 心跳于241秒前 · 2026-10-16 19:30

✦ 量化股权信号 计算方式说明

减持
  • 最近一期（2026/Q3）披露持股的机构数量减少了3家。
  • 机构持股总比例下降了0.6个百分点。

机构持股

机构持股比例
122.81% -0.58pp
机构数量
297 -3
数据截至
2026/Q3 较上一报告期

持股变动 vs 资金流向

方向一致

机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Mutual Fund59.69%
Hedge Fund43.07%
Public Company10.26%
VC/PE Fund6.22%
Private Company2.08%
Individual/Insider1.07%
Insurance Company0.58%
Government Pension Fund0.58%
Family Office/Trust0.33%

主要股东 截至 2026-06-30

BlackRock 10.10% · 9.02M 股
Kynam Capital Management, LP 9.02% · 8.05M 股
State Street Global Advisors 6.34% · 5.66M 股
The Goldman Sachs Group, Inc. 6.09% · 5.44M 股
Vanguard Capital Management, LLC 5.11% · 4.56M 股
Deerfield Management Company, L.P. 4.23% · 3.78M 股
Eversept Partners, L.P. 3.13% · 2.80M 股
Bank of America Corporation 2.94% · 2.62M 股
Geode Capital Management, LLC 2.89% · 2.58M 股
Hood River Capital Management LLC 2.87% · 2.56M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 26次买入 · 22次卖出

姓名职务持股比例
Dennis Podlesak Independent Chairperson 0.20%
Jennifer Jarrett Independent Director 0.10%
Pierre Legault Independent Director 0.10%
Keith Katkin Independent Director 0.10%
Martin Huber Independent Director 0.08%
Michael Metzger Chief Executive Officer 0.07%
Nicholas Botwood Head of Research & Development and Chief Medical Officer 0.07%
Keith Goldan CFO, Treasurer & Chief Accounting Officer 0.03%
Aleksandra Rizo Director 0.03%
Neil Gallagher President of Research & Development --

内部人交易 最近的 Form 4 申报记录

日期姓名职务类型股数价格
2026-07-07 Michael Metzger Chief Executive Officer Derivative Exercise and Sale -32,375 $6.38–24.24
2026-06-11 Nicholas Botwood Head of Research & Development and Chief Medical Officer Derivative Exercise and Sale -53,750 $13.82–18.14
2026-06-11 Nicholas Botwood Head of Research & Development and Chief Medical Officer Intent to Sell (Form 144) -31,235 $18.14
2026-06-10 Nicholas Botwood Head of Research & Development and Chief Medical Officer Automatic Disposition -11,765 $18.00
2026-05-31 Keith Goldan CFO, Treasurer & Chief Accounting Officer Open Market Disposition -1,177 $18.99
2026-05-31 Michael Metzger Chief Executive Officer Open Market Disposition -6,847 $18.99
2026-02-08 Keith Goldan CFO, Treasurer & Chief Accounting Officer Open Market Disposition -3,410 $21.03
2026-02-08 Michael Metzger Chief Executive Officer Open Market Disposition -17,159 $21.03
2026-02-05 Keith Goldan CFO, Treasurer & Chief Accounting Officer Open Market Disposition -2,082 $20.62
2026-02-05 Michael Metzger Chief Executive Officer Open Market Disposition -7,412 $20.62
2026-02-03 Keith Katkin Independent Director Other Acquisition +24,000 --
2026-02-03 Pierre Legault Independent Director Other Acquisition +24,000 --
2026-02-03 Keith Goldan CFO, Treasurer & Chief Accounting Officer Other Acquisition +52,250 --
2026-02-03 Keith Goldan CFO, Treasurer & Chief Accounting Officer Other Derivative Acquisition +118,000 $20.43
2026-02-03 Dennis Podlesak Independent Chairperson Other Acquisition +48,000 --
2026-02-03 Michael Metzger Chief Executive Officer Other Acquisition +217,600 --
2026-02-03 Michael Metzger Chief Executive Officer Other Derivative Acquisition +440,000 $20.43
2026-02-03 Jennifer Jarrett Independent Director Other Acquisition +24,000 --
2026-02-03 Aleksandra Rizo Director Other Acquisition +24,000 --
2026-02-03 Martin Huber Independent Director Other Acquisition +24,000 --

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。

辛迪制药 讨论区 0 条评论

发表评论